The US Federal Trade Commission has ordered Novartis to sell its injectable miotic, Miochol-E (acetylcholine chloride) to Bausch & Lomb as part of a settlement to resolve complaints concerning the proposed acquisition of eyecare firm Alcon.
Novartis and Alcon sell the only two marketed miotics, Miochol-E and Miostat. Miotic sales reached $12.4 million last year, with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?